دورية أكاديمية
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN.
| العنوان: | Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN. |
|---|---|
| المؤلفون: | Valassi E; IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain.; Universitat Internacional de Catalunya (UIC), Barcelona, Spain., Castinetti F; Department of Endocrinology, Aix Marseille University, AP-HM, INSERM, Marseille Medical Genetics, Marmara Institute, La Conception Hospital, Marseille, France., Ferriere A; Department of Endocrinology, Diabetes and Nutrition, University of Bordeaux, Bordeaux, France., Tsagarakis S; Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece., Feelders RA; Erasmus Medical Center, Division of Endocrinology, Department of Internal Medicine, Rotterdam, The Netherlands., Netea-Maier RT; Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Droste M; Praxis für Endokrinologie Dr. med. Michael Droste, Oldenburg, Germany., Strasburger CJ; Division of Clinical Endocrinology, Department of Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany., Maiter D; Service d'Endocrinologie et Nutrition, Cliniques universitaires Saint Luc, Brussels, Belgium., Kastelan D; Department of Endocrinology, University Hospital Zagreb, Zagreb, Croatia., Chanson P; Institut National de la Santé et de la Recherche Médicale, U1185, Le Kremlin, Bicêtre, Paris, France., Webb SM; IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Demtröder F; Zentrum für Endokrinologie, Diabetologie, Rheumatologie Dr. Demtröder & Kollegen, Dortmund, Germany., Pirags V; Paula Stradiņa klīniskā universitātes slimnīca, Riga, Latvia., Chabre O; Hospitalier Universitaire, Grenoble, France., Franz H; Lohmann & Birkner Health Care Consultimg GmbH, Berlin, Germany., Santos A; IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Reincke M; Medizinische Klinik UND Poliklinik IV, Campus Innestadt, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany. |
| المصدر: | Endocrine-related cancer [Endocr Relat Cancer] 2022 Nov 02; Vol. 29 (12), pp. 681-691. Date of Electronic Publication: 2022 Nov 02 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: BioScientifica Country of Publication: England NLM ID: 9436481 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1479-6821 (Electronic) Linking ISSN: 13510088 NLM ISO Abbreviation: Endocr Relat Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Bristol, UK : BioScientifica Original Publication: Woodlands, Almondsbury, Bristol, UK : Published for the Society of Endocrinology by the Journal of Endocrinology Ltd., 1994- |
| مواضيع طبية MeSH: | Nelson Syndrome*/diagnosis , Nelson Syndrome*/etiology , Nelson Syndrome*/surgery , Pituitary ACTH Hypersecretion*, Humans ; Adrenalectomy/adverse effects ; Corticotrophs |
| مستخلص: | Corticotroph tumor progression after bilateral adrenalectomy/Nelson's syndrome (CTP-BADX/NS) is a severe complication of bilateral adrenalectomy (BADX). The aim of our study was to investigate the prevalence, presentation and outcome of CTP-BADX/NS in patients with Cushing's disease (CD) included in the European Registry on Cushing's Syndrome (ERCUSYN). We examined data on 1045 CD patients and identified 85 (8%) who underwent BADX. Of these, 73 (86%) had follow-up data available. The median duration of follow-up since BADX to the last visit/death was 7 years (IQR 2-9 years). Thirty-three patients (45%) experienced CTP-BADX/NS after 3 years (1.5-6) since BADX. Cumulative progression-free survival was 73% at 3 years, 66% at 5 years and 46% at 10 years. CTP-BADX/NS patients more frequently had a visible tumor at diagnosis of CD than patients without CTP-BADX/NS (P < 0.05). Twenty-seven CTP-BADX/NS patients underwent surgery, 48% radiotherapy and 27% received medical therapy. The median time since diagnosis of CTP-BADX/NS to the last follow-up visit was 2 years (IQR, 1-5). Control of tumor progression was not achieved in 16 of 33 (48%) patients, of whom 8 (50%) died after a mean of 4 years. Maximum adenoma size at diagnosis of CD was associated with further tumor growth in CTP-BADX/NS despite treatment (P = 0.033). Diagnosis of CTP-BADX/NS, older age, greater UFC levels at diagnosis of CD and initial treatment predicted mortality. In conclusion, CTP-BADX/NS was reported in 45% of the ERCUSYN patients who underwent BADX, and control of tumor growth was reached in half of them. Future studies are needed to establish effective strategies for prevention and treatment. |
| فهرسة مساهمة: | Keywords: Cushing’s disease; Nelson’s syndrome; bilateral adrenalectomy; corticotroph adenoma |
| تواريخ الأحداث: | Date Created: 20221005 Date Completed: 20221220 Latest Revision: 20231105 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1530/ERC-22-0074 |
| PMID: | 36197784 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1479-6821 |
|---|---|
| DOI: | 10.1530/ERC-22-0074 |